Mannkind (MNKD) Liabilities and Shareholders Equity (2010 - 2026)
Mannkind (MNKD) reported Liabilities and Shareholders Equity of $744.4 million for Q1 2026, up 81.5% year-over-year from $410.1 million in Q1 2025, and down 6.03% on a QoQ basis from $792.2 million in Q4 2025.
Mannkind (MNKD) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $744.4 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 81.5% year-over-year to $744.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 42.69% YoY) and the FY2025 annual result came in at $792.2 million, up 101.14% from the prior year.
- Liabilities and Shareholders Equity declined to $744.4 million in Q1 2026 per MNKD's latest filing, from $792.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $792.2 million in Q4 2025 and bottomed at $285.8 million in Q2 2022.
- The 5-year median for Liabilities and Shareholders Equity is $410.1 million (2025), against an average of $425.1 million.
- The widest annual swing landed in 2024, when Liabilities and Shareholders Equity declined 17.12%; it then jumped 101.14% in 2025.
- Tracing MNKD's Liabilities and Shareholders Equity over 5 years: stood at $295.3 million in 2022, then soared by 60.93% to $475.2 million in 2023, then slipped by 17.12% to $393.8 million in 2024, then jumped by 101.14% to $792.2 million in 2025, then slipped by 6.03% to $744.4 million in 2026.
- Per Business Quant, the three latest MNKD Liabilities and Shareholders Equity figures stand at $744.4 million (Q1 2026), $792.2 million (Q4 2025), and $494.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | 744.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 744.40 Mn |
| Dec 31, 2025 | 792.18 Mn |
| Sep 30, 2025 | 494.64 Mn |
| Jun 30, 2025 | 411.70 Mn |
| Mar 31, 2025 | 410.14 Mn |
| Dec 31, 2024 | 393.84 Mn |
| Sep 30, 2024 | 464.20 Mn |
| Jun 30, 2024 | 443.84 Mn |
| Mar 31, 2024 | 480.88 Mn |
| Dec 31, 2023 | 475.20 Mn |
| Sep 30, 2023 | 320.33 Mn |
| Jun 30, 2023 | 313.42 Mn |
| Mar 31, 2023 | 298.14 Mn |
| Dec 31, 2022 | 295.28 Mn |
| Sep 30, 2022 | 293.84 Mn |
| Jun 30, 2022 | 285.80 Mn |
| Mar 31, 2022 | 308.32 Mn |
| Dec 31, 2021 | 321.16 Mn |
| Sep 30, 2021 | 238.21 Mn |
| Jun 30, 2021 | 252.79 Mn |
| Mar 31, 2021 | 319.38 Mn |
| Dec 31, 2020 | 108.61 Mn |
| Sep 30, 2020 | 95.68 Mn |
| Jun 30, 2020 | 102.78 Mn |
| Mar 31, 2020 | 80.21 Mn |
| Dec 31, 2019 | 93.73 Mn |
| Sep 30, 2019 | 95.14 Mn |
| Jun 30, 2019 | 81.80 Mn |
| Mar 31, 2019 | 100.96 Mn |
| Dec 31, 2018 | 107.71 Mn |
| Sep 30, 2018 | 45.36 Mn |
| Jun 30, 2018 | 62.16 Mn |
| Mar 31, 2018 | 61.88 Mn |
| Dec 31, 2017 | 84.58 Mn |
| Sep 30, 2017 | 56.48 Mn |
| Jun 30, 2017 | 79.37 Mn |
| Mar 31, 2017 | 85.19 Mn |
| Dec 31, 2016 | 107.06 Mn |
| Sep 30, 2016 | 96.13 Mn |
| Jun 30, 2016 | 139.43 Mn |
| Mar 31, 2016 | 93.27 Mn |
| Dec 31, 2015 | 126.41 Mn |
| Sep 30, 2015 | 278.01 Mn |
| Jun 30, 2015 | 352.55 Mn |
| Mar 31, 2015 | 360.02 Mn |
| Dec 31, 2014 | 394.44 Mn |
| Sep 30, 2014 | 386.82 Mn |
| Jun 30, 2014 | 236.31 Mn |
| Mar 31, 2014 | 224.55 Mn |
| Dec 31, 2013 | 258.65 Mn |
| Sep 30, 2013 | 287.61 Mn |
| Jun 30, 2013 | 212.43 Mn |
| Mar 31, 2013 | 215.20 Mn |
| Dec 31, 2012 | 251.31 Mn |
| Sep 30, 2012 | 210.33 Mn |
| Jun 30, 2012 | 240.39 Mn |
| Mar 31, 2012 | 251.42 Mn |
| Dec 31, 2011 | 199.55 Mn |
| Sep 30, 2011 | 224.01 Mn |
| Jun 30, 2011 | 228.36 Mn |
| Dec 31, 2010 | 277.26 Mn |